Maris stepped down from his perch at Google parent company Alphabet, where he ran one of Silicon Valley’s biggest corporate investment groups, in August. Sources close to Maris tell Recode that regulatory filings related to a $240 million-plus funding round—whose exact purpose is, as of yet, unknown, other than its relation to health care investments—will be released as early as this week. The fund is dubbed “Section 32.”
Click here to subscribe to Brainstorm Health Daily, our brand new newsletter about health innovations.
Fortune has reached out to Mathis for comment and will update this post if he responds.
Maris has considerable history in health care from his time at Google Ventures (GV) and personal life alike. He was trained as a neuroscientist and led GV to ally with a number of new innovative health and tech firms, including Flatiron Health and Foundation Medicine.
It’s still unclear exactly what kind of health technologies that Maris may fund with his new venture group. But he has previously expressed a major interest in both aging-related diseases and cancers—two medical spaces that have clearly drawn the interest of Silicon Valley outfits, including Google’s own Calico and number of prominent tech scions like Sean Parker.